Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALS-L1023 in Patients With Non-alcoholic Steatohepatitis (NASH)
NCT04342793Phase 2Completed
- Sponsor
- AngioLab, Inc.
- Start
- Dec 2019
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ALS-L1023 in Nonalcoholic steatohepatitis (NASH) (3 arms), sponsored by AngioLab, Inc. Primary endpoints: Change in liver fat percentage measured by MRI-PDFF at 24 weeks, Change in liver fibrosis measured by MRE at 24 weeks and 3 more. Started Dec 2019; status: completed.
02
Drugs
ALS-L1023
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04342793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04342793.